VLST Corporation is a technology company.
VLST Corporation has raised $55.0M across 1 funding round.
VLST Corporation has raised $55.0M in total across 1 funding round.
VLST Corporation has raised $55.0M in total across 1 funding round.
VLST Corporation's investors include ARCH Venture Partners.
VLST Corporation (Viral Logic Systems Technology) is a privately held biotechnology company that developed a streamlined platform combining bioinformatics and proteomics to identify novel therapeutic targets and biologic molecules, primarily for autoimmune, inflammatory disorders, and later oncology.[1][2][3] The platform accelerates drug discovery by studying viral proteins that modulate immune responses, yielding candidates with higher clinical success potential for diseases like multiple sclerosis, lupus, psoriasis, rheumatoid arthritis, and cancer; it serves pharmaceutical partners through licensing deals, including antibody candidates and its proprietary engine.[1][5][6] VLST raised $55 million in Series B financing and achieved pivotal exits via strategic partnerships, transferring programs for further development while retaining milestone payments.[1][5]
Founded in 2004 by Immunex veterans Dr. Craig Smith (co-founder and Chief Scientific Officer) and Steve Wiley, VLST emerged from their expertise in viral genomics and immune regulation.[1][2] At Immunex (later Amgen), Smith cloned the TNF receptor and engineered Enbrel for rheumatoid arthritis treatment, inspiring VLST's core idea: analyze proteins viruses secrete to evade immune attacks, repurposing insights for human autoimmune therapies.[1][2] Early backing came from Seattle's Accelerator incubator and investors like WRF Capital, OVP Venture Partners (via Gerry L.), and ARCH Venture Partners; the company gained traction with its platform identifying immunomodulatory targets, leading to in-licensed programs and a $55 million Series B round.[1][2][5]
VLST rode the early 2000s biotech wave in systems biology and viral-inspired immunomodulation, aligning with rising demand for biologics in autoimmune diseases amid successes like Enbrel and Humira.[1][2] Its timing capitalized on post-genomics advances in proteomics/bioinformatics, enabling faster target discovery when traditional pharma pipelines faced high failure rates (over 90% in clinical stages).[1] Market forces favoring outsourced innovation and strategic partnerships propelled VLST's model, influencing the ecosystem by validating viral logic for drug design—now echoed in modern immuno-oncology and inflammation therapies—and bridging startups with big pharma resources.[1][4]
VLST's strategic exits position it as a model for biotech efficiency, with milestone payments potentially fueling new ventures in its viral-inspired platform amid booming immuno-oncology and autoimmune markets.[1][4] Trends like AI-enhanced proteomics and combination biologics will shape successors, amplifying VLST's influence on rational drug discovery. As partners advance its candidates, VLST exemplifies how focused platforms drive ecosystem progress, tying back to its mission of streamlining therapeutics for unmet needs in immune disorders.
VLST Corporation has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Series B in June 2006.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2006 | $55.0M Series B | ARCH Venture Partners |